Breast Tumour Size Measurement by Field Cycling Imaging

Starting soon

Conditions studied: Breast Cancer, Ductal Carcinoma In Situ

In brief

The goal of this study is to test if a new type of MRI scanner, called Field-Cycling Imaging (FCI), can accurately estimate tumour size in patients with a type of breast cancer called ductal carcinoma in situ (DCIS). The main question it aims to answer is: Can FCI accurately estimate DCIS lesion size compared with histology results? Participants will have a standard MRI scan and an FCI scan before undergoing surgery to remove the tumour.

Key facts

Study ID

NCT07492043

Run by

University of Aberdeen

People needed

12

Starts

2026-04-01

Expected to finish

2026-12-01

Last updated by the study team

2026-03-25

Who can join

Age: 18 and older. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• Females ≥ 18 years old.
• Subjects diagnosed with DCIS on initial biopsy.
• Lesion size >1 cm on imaging.
• Subjects undergoing surgery as part of their treatment.
• Able to fit comfortably in the scanners.
• Able to understand written and spoken English.

You may not qualify if…

• Subjects undergoing chemotherapy or hormonal therapy.
• Individuals unable to give informed consent.
• Contra-indications to MRI scanning such as implantable cardiac devices.
• Known allergy to contrast agent.

Where it is running

• University of Aberdeen — Aberdeen, United Kingdom

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.